This article is ratedStart-class on Wikipedia'scontent assessment scale. It is of interest to the followingWikiProjects:

PharmacologyMid‑importance This article is within the scope ofWikiProject Pharmacology, a collaborative effort to improve the coverage ofPharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can jointhe discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology Mid This article has been rated asMid-importance on theproject's importance scale. MedicineMid‑importance This article is within the scope ofWikiProject Medicine, which recommends that medicine-related articles follow theManual of Style for medicine-related articles and that biomedical information in any articleuse high-quality medical sources. Please visit the project page for details or ask questions atWikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine Mid This article has been rated asMid-importance on theproject's importance scale.

Ideal sources for Wikipedia's health content are defined in the guidelineWikipedia:Identifying reliable sources (medicine) and are typicallyreview articles. Here are links topossibly useful sources of information aboutTremelimumab. PubMed providesreview articles from the past five years (limit tofree review articles) TheTRIP database providesclinical publications about evidence-based medicine. Other potential sources include:Centre for Reviews and Dissemination andCDC

ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS. Phase III trials ongoing. -Rod57 (talk)00:13, 9 February 2016 (UTC)[reply]

As reported at[1], this is a phase Ib study (study 006), which means it's an early exploratory study. According to the content guidelineWP:MEDRS, unless there is a particular reason for an exception, this report is completely and utterly irrelevant in this encyclopedic concept space, until further information develops. By convention, people are free to put whatever preliminary speculations or outright rubbish they want on Talk pages. Other editors are then free to come along and criticize the embarassingly poetic fancy of placing premature, naive, buzzing gossip here. This response denounces without reservation this wobbly reference as a (presumably unintentional) bewilderingly misguided promotion of a particular commercial confection, which has not been adequately tested. As a relevant comparative benchmark, there are several approved medications within the immunotherapy concept space, making this reference all the more flagrantly speculative and contextually unscrupulous.FeatherPluma (talk)17:45, 5 March 2016 (UTC)[reply]

• Start-Class pharmacology articles
• Mid-importance pharmacology articles
• WikiProject Pharmacology articles
• Start-Class medicine articles
• Mid-importance medicine articles
• All WikiProject Medicine pages